Perrigo (PRGO) Competitors $23.56 +0.54 (+2.32%) Closing price 03:59 PM EasternExtended Trading$23.60 +0.04 (+0.15%) As of 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PRGO vs. CORT, JAZZ, SUPN, PCRX, NKTR, OMER, ASMB, CPIX, LLY, and JNJShould you be buying Perrigo stock or one of its competitors? The main competitors of Perrigo include Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), and Johnson & Johnson (JNJ). These companies are all part of the "pharmaceuticals" industry. Perrigo vs. Its Competitors Corcept Therapeutics Jazz Pharmaceuticals Supernus Pharmaceuticals Pacira BioSciences Nektar Therapeutics Omeros Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson Corcept Therapeutics (NASDAQ:CORT) and Perrigo (NYSE:PRGO) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations. Which has more risk & volatility, CORT or PRGO? Corcept Therapeutics has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Which has higher valuation & earnings, CORT or PRGO? Corcept Therapeutics has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorcept Therapeutics$716.08M10.33$141.21M$1.1362.12Perrigo$4.37B0.74-$171.80M-$0.58-40.63 Is CORT or PRGO more profitable? Corcept Therapeutics has a net margin of 18.51% compared to Perrigo's net margin of -1.86%. Corcept Therapeutics' return on equity of 20.10% beat Perrigo's return on equity.Company Net Margins Return on Equity Return on Assets Corcept Therapeutics18.51% 20.10% 16.20% Perrigo -1.86%9.09%3.96% Does the media favor CORT or PRGO? In the previous week, Corcept Therapeutics had 14 more articles in the media than Perrigo. MarketBeat recorded 26 mentions for Corcept Therapeutics and 12 mentions for Perrigo. Perrigo's average media sentiment score of 1.25 beat Corcept Therapeutics' score of 1.14 indicating that Perrigo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 19 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Perrigo 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of CORT or PRGO? 93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 20.8% of Corcept Therapeutics shares are held by insiders. Comparatively, 0.4% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate CORT or PRGO? Corcept Therapeutics currently has a consensus price target of $134.50, suggesting a potential upside of 91.62%. Perrigo has a consensus price target of $33.00, suggesting a potential upside of 40.04%. Given Corcept Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Corcept Therapeutics is more favorable than Perrigo.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corcept Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Perrigo 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 SummaryCorcept Therapeutics beats Perrigo on 12 of the 16 factors compared between the two stocks. Get Perrigo News Delivered to You Automatically Sign up to receive the latest news and ratings for PRGO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRGO vs. The Competition Export to ExcelMetricPerrigoMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$3.24B$10.48B$5.76B$20.88BDividend Yield5.11%1.90%3.91%3.59%P/E Ratio-40.6320.1830.7828.34Price / Sales0.7428.27457.7654.38Price / Cash4.5024.9525.2217.82Price / Book0.743.479.364.54Net Income-$171.80M$209.94M$3.26B$992.74M7 Day Performance2.26%1.01%1.83%0.29%1 Month Performance-12.56%9.97%3.69%1.13%1 Year Performance-14.65%-11.39%28.88%11.00% Perrigo Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRGOPerrigo4.9588 of 5 stars$23.57+2.3%$33.00+40.0%-16.7%$3.24B$4.37B-40.638,379Positive NewsAnalyst UpgradeInsider TradeCORTCorcept Therapeutics4.7205 of 5 stars$71.97-0.5%$134.50+86.9%+111.2%$7.58B$675.04M63.69300Positive NewsJAZZJazz Pharmaceuticals4.5073 of 5 stars$110.75-0.5%$181.43+63.8%+6.0%$6.70B$4.09B-16.462,800SUPNSupernus Pharmaceuticals2.129 of 5 stars$40.57-1.6%$41.00+1.1%+24.4%$2.27B$661.82M35.28580Insider TradePCRXPacira BioSciences3.4225 of 5 stars$25.19+0.0%$25.75+2.2%+92.3%$1.13B$700.97M-9.06720NKTRNektar Therapeutics4.345 of 5 stars$22.47-2.6%$88.33+293.1%+46.3%$278.79M$87.25M-2.55220Positive NewsOMEROmeros4.1459 of 5 stars$4.14+2.0%$18.00+334.8%+3.4%$255.69MN/A-1.56210Earnings ReportASMBAssembly Biosciences4.0776 of 5 stars$23.60-1.5%$33.00+39.8%+80.1%$180.26M$33.25M-4.23100Analyst ForecastHigh Trading VolumeCPIXCumberland Pharmaceuticals0.5029 of 5 stars$2.84-12.1%N/A+119.3%$42.49M$42.07M-12.9180Analyst UpgradeLLYEli Lilly and Company4.9993 of 5 stars$635.46+1.6%$977.65+53.8%-24.2%$602.25B$53.26B41.5347,000Trending NewsAnalyst DowngradeHigh Trading VolumeJNJJohnson & Johnson4.8442 of 5 stars$173.98+0.4%$174.50+0.3%+10.6%$418.99B$90.63B18.61138,100Positive News Related Companies and Tools Related Companies Corcept Therapeutics Competitors Jazz Pharmaceuticals Competitors Supernus Pharmaceuticals Competitors Pacira BioSciences Competitors Nektar Therapeutics Competitors Omeros Competitors Assembly Biosciences Competitors Cumberland Pharmaceuticals Competitors Eli Lilly and Company Competitors Johnson & Johnson Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PRGO) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perrigo Company plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Perrigo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access